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To the Editor: We read with interest the results of the clinical
trial comparing biocompatible with standard solutions in
peritoneal dialysis.1 We believe that the authors’ claim of
noninferiority of biocompatible solutions compared to
standard solutions is not supported by their data. If the
difference in the mean of urea and creatinine clearance,
DnCrCl, between the two groups was 6.5 l per week and its
standard deviation was 6 l per week then its 95% confidence
interval was 18.42 to 5.42 l per week and the corresponding
figures in ml/min units were 1.87 ml/min (1.83 to
0.54 ml/min).2 As a result, a noninferiority hypothesis set
on the assumption that the difference is less than 1 ml/min
cannot be maintained as the lower limit of the 95%
confidence interval, 1.83 ml/min, is far lower than
1 ml/min.
We do not understand how the probabilities of actual
differences in DnCrCl or DUvol being greater than particular
figures were calculated, especially DnCrCl, highly incon-
sistent with its confidence interval. Standard, frequentist,
statistics can only calculate the probability that a test statistic
would be as extreme as or more extreme than observed if the
null hypotheses were true, the P-value. Alternatively, Bayesian
statistics can provide those probabilities,3 but no mention
was made of it in the article.
Further studies with larger sample sizes are needed also to
assess whether biocompatible solutions are indeed noninfer-
ior to standard solutions.
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I thank Dr Garcia-Lopez for asking me to clarify the
statistics I used in my article.
Existing publications (including his own1) suggest that
biocompatible peritoneal dialysis solutions would be super-
ior than standard. With this in mind, we wished to
determine if patients using biocompatible peritoneal dialysis
solutions would have a smaller decrement in nCrCl. We
decided to use a predefined cutoff that we felt was clinically
relevant, of 1 ml/min; that is inferiority of standard solutions
would be proven if DnCrClbiocom–DnCrClstand4þ 1 ml/min.
Dr Garcia Lopez has correctly calculated that the 95%
confidence interval for DnCrClbiocom–DnCrClstand was 1.83
to þ 0.54 ml/min. As þ 1 ml/min falls outside this range, we
could not demonstrate that standard solutions were inferior
(that is, we demonstrated noninferiority).
The difference between the expected DnCrCl (þ 1 ml/min)
and the observed DnCrCl (0.64 ml/min) was 1.64 ml/min.
The standard error was 0.6, therefore the observed DnCrCl
was42.7 s.e. outside the expected DnCrCl. The probability of
randomly selecting a group of normally distributed patients
who lie42.7 s.e. from the expected mean is B0.003.
We claimed that standard solutions are not inferior to
biocompatible (with regard to preserving residual renal
function in unselected incident peritoneal dialysis
patients). I therefore strongly refute any suggestions that
our claims are not supported by data.
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To the Editor: Davenport et al.1 were able to write an article
on hypertension control in dialysis patients of several
thousand words in length without mentioning the word salt.
This is curious given the wide publicity that an article by
Cook et al.2 on the highly significant benefit obtained with
5–6 g salt intake per day in reducing cardiovascular morbidity
and mortality in a ‘prehypertensive healthy population’. The
study, over a 10-year period, was randomized and controlled,
and involved several thousand individuals.2 This latter
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publication was widely reported in the UK press and
television in April 2007. One must assume that this implies
that compliance with a salt-restricted diet was considered
irrelevant or was not even considered by Davenport et al. The
editorial in the same issue of Kidney International mentions
in passing the possible benefits of salt restriction but states
there is no evidence-based medicine to support the benefit of
salt restriction in the treatment of hypertension in dialysis
patients, and implies as it is difficult to achieve because of the
high salt content in processed food, drug treatment of
hypertension is an acceptable alternative.3 Thus, the aban-
donment of salt restriction in dialysis patients in the United
Kingdom seems to have followed that of the United States. A
fact that was lamented by Scribner in 1999.4 The improve-
ment of the relevant revised Kidney Disease Outcomes
Quality Initiative guidelines 20065 seems to have fallen on
deaf ears. This suspicion is confirmed by the incredibly
minimalist paragraphs dedicated to salt restriction in the
National Institute for Health and Clinical Excellence guide-
lines on the treatment of hypertension in the United
Kingdom.6 It is of interest to note that the authors have
rediscovered a very well-known observation that intradialytic
hypotension was very much commoner in patients receiving
antihypertensive medication taken on dialysis days. A
problem rarely seen when hypertension was controlled by
dietary salt restriction alone.
The authors conclude that the benefit of strict blood
pressure control targets is not evidence based and that
attempts to reach them may be more harmful than beneficial.
The unchallenged best survival data in the world of end-stage
renal disease patients treated by hemodialysis with both long
and short hours shared one common factor—an obsessive
compliance with a 5 g per day salt intake in their popula-
tions.7,8 Furthermore, a recent study comparing equivalent
blood pressure control by salt restriction vs antihypertensive
drugs in two hemodialysis centers revealed a significantly
higher incidence of cardiovascular complications in the
center using antihypertensive agents.
If one must wait for a perfectly designed randomized
control study to disprove the superiority of salt restriction over
antihypertensive agents in the control of hypertension in end-
stage renal disease patients it will indeed be a sad state of affairs.
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To keep within the word limit, not all the information
obtained during this audit of more than 2000 adult
hemodialysis patients could be presented. As Professor
Shaldon and colleagues point out, there has been a well-
recognized association between sodium balance and blood
pressure in patients with chronic kidney disease. In a
previous audit, we have reported a relationship between
improved blood pressure control and reduced interdialytic
weight gains with negative sodium balance in chronic
hemodialysis patients.1 Our standard practice is to provide
hemodialysis patients with appropriate dietetic advice to
restrict daily dietary sodium intake to 100–120 mmol/day.
However, there have been some changes to the dialysis
population of the Royal Free Hospital, since Professor
Shaldon last worked here. The hospital now serves a
multiethnic population, with some 146 different languages
officially recognized. We accept that this does impact on
the ability of our dieticians to effectively communicate
with patients, and appropriately educate them to restrict
their dietary sodium intake.
However our paper was not about hypertension control
in hemodialysis patients, as suggested by professor
Shaldon and colleagues, but rather an audit of whether
dialysis centers achieved specified pre- and post-dialysis
blood pressure targets. There is increasing data to suggest
that simple pre- and post-hemodialysis blood pressure
measurements may not necessarily accurately reflect
interdialytic blood pressure control in hemodialysis
patients.2 This may account for the differences observed
in terms of cardiovascular risk, and blood pressure control
in the general population compared to hemodialysis
patients.3 The UK Renal Registry collects pre- and post-
hemodialysis blood pressure recordings at regular intervals
from UK kidney dialysis centers, and produces a report
ranking centers according to their compliance with pre-
and post-dialysis blood pressure targets,3 which had been
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